: Reata’s new rare-disease drug will cost $370,000 per year


Reata Pharmaceuticals Inc.’s RETA, +200.38% newly approved treatment for Friedreich’s ataxia will have a wholesale acquisition price of $370,000 per year, the company told investors on Tuesday night. The Food and Drug Administration on Tuesday approved the drug, Skyclarys, which treats a rare nervous-system disease that affects about 4,500 diagnosed patients in the U.S. Reata’s stock was up about 195% in trading on Wednesday afternoon, a day after the FDA approval was announced.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Student-loan forgiveness: There is no ‘backup plan,’ says Biden official. ‘We have one plan, it’s the plan that we’ve announced.’
Next articleShould stock investors take profits or buy dips in a ‘make or break’ March?


Please enter your comment!
Please enter your name here